Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)
Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter. - Experimental Design: Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing. Patient...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 3, 2016
|
| In: |
Clinical cancer research
Year: 2016, Jahrgang: 22, Heft: 19, Pages: 4797-4806 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-15-3153 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-15-3153 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/22/19/4797 
|
| Verfasserangaben: | Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, and Monika E. Hegi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1725591383 | ||
| 003 | DE-627 | ||
| 005 | 20220818161745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200727s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-15-3153 |2 doi | |
| 035 | |a (DE-627)1725591383 | ||
| 035 | |a (DE-599)KXP1725591383 | ||
| 035 | |a (OCoLC)1341347863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 29 |2 sdnb | ||
| 100 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 245 | 1 | 0 | |a Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) |c Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, and Monika E. Hegi |
| 264 | 1 | |c May 3, 2016 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.07.2020 | ||
| 520 | |a Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter. - Experimental Design: Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing. Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg). Primary endpoint was overall survival at 12 months (OS12). A positive signal was considered >38 patients alive at 12 months in the per protocol population. A noncomparative reference arm of 54 patients evaluated the assumptions on OS12 in a standard-treated cohort of patients. Prespecified post hoc analyses of markers reflecting target activation were performed. - Results: Both therapies were administered per protocol with a median of 13 cycles of maintenance temsirolimus. Median age was 55 and 58 years in the temsirolimus and standard arms, the WHO performance status 0 or 1 for most patients (95.5%). In the per protocol population, 38 of 54 patients treated with temsirolimus reached OS12. The actuarial 1-year survival was 72.2% [95% confidence interval (CI), 58.2-82.2] in the temozolomide arm and 69.6% (95% CI, 55.8-79.9) in the temsirolimus arm [hazard ratio (HR) 1.16; 95% CI, 0.77-1.76; P = 0.47]. In multivariable prognostic analyses of clinical and molecular factors, phosphorylation of mTORSer2448 in tumor tissue (HR 0.13; 95% CI, 0.04-0.47; P = 0.002), detected in 37.6%, was associated with benefit from temsirolimus. - Conclusions: Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter. Phosphorylation of mTORSer2448 in the pretreatment tumor tissue may define a subgroup benefitting from mTOR inhibition. Clin Cancer Res; 22(19); 4797-806. ©2016 AACR. | ||
| 700 | 1 | |a Platten, Michael |d 1971- |e VerfasserIn |0 (DE-588)121627780 |0 (DE-627)081431848 |0 (DE-576)261969811 |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 22(2016), 19, Seite 4797-4806 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:19 |g pages:4797-4806 |g extent:10 |a Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-15-3153 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/22/19/4797 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200727 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |d 911100 |e 910000PW122759869 |e 911100PW122759869 |k 0/910000/ |k 1/910000/911100/ |p 10 | ||
| 998 | |g 121627780 |a Platten, Michael |m 121627780:Platten, Michael |d 910000 |d 911100 |e 910000PP121627780 |e 911100PP121627780 |k 0/910000/ |k 1/910000/911100/ |p 4 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1725591383 |e 3729482335 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"recId":"1725591383","type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 27.07.2020"],"title":[{"title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","title_sort":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)"}],"origin":[{"dateIssuedDisp":"May 3, 2016","dateIssuedKey":"2016"}],"person":[{"family":"Wick","given":"Wolfgang","role":"aut","display":"Wick, Wolfgang"},{"family":"Platten","given":"Michael","role":"aut","display":"Platten, Michael"},{"display":"Wick, Antje","family":"Wick","role":"aut","given":"Antje"}],"relHost":[{"corporate":[{"display":"American Association for Cancer Research","role":"isb"}],"name":{"displayForm":["American Association for Cancer Research"]},"pubHistory":["1.1995 -"],"id":{"zdb":["2036787-9"],"issn":["1557-3265"],"eki":["325489971"]},"part":{"year":"2016","volume":"22","pages":"4797-4806","issue":"19","text":"22(2016), 19, Seite 4797-4806","extent":"10"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"325489971","disp":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)Clinical cancer research","origin":[{"publisher":"AACR","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}]}],"id":{"eki":["1725591383"],"doi":["10.1158/1078-0432.CCR-15-3153"]},"name":{"displayForm":["Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, and Monika E. Hegi"]}} | ||
| SRT | |a WICKWOLFGAPHASEIISTU3201 | ||